HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ziegler, D. Articles by Chappell, A. S. Search for Related Content PubMed PubMed Citation Articles by Ziegler, D. Articles by Chappell, A. S. Social Bookmarking                What's this?

Impact of Disease Characteristics on the Efficacy of Duloxetine in Diabetic Peripheral Neuropathic Pain

¹ German Diabetes Center, Leibniz Institute at the Heinrich Heine University, Düsseldorf, Germany
² Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana

Address correspondence and reprint requests to Prof. Dr. Dan Ziegler, FRCPE, German Diabetes Center, Leibniz Institute at the Heinrich Heine University, Auf’m Hennekamp 65, 40225 Düsseldorf, Germany. E-mail: dan.ziegler{at}ddz.uni-duesseldorf.de

OBJECTIVE—To evaluate the impact of baseline disease variables related to diabetes and diabetic neuropathy severity on efficacy and safety of duloxetine in the management of diabetic peripheral neuropathic pain.

RESEARCH DESIGN AND METHODS—The impact of baseline conditions was evaluated using the data from three pooled placebo-controlled studies for combined duloxetine, doses of 60 mg q.d. and 60 mg b.i.d., versus placebo. The primary efficacy measure was the weekly mean of 24-h average pain severity, and night pain was the secondary measure. Safety and tolerability were assessed.

RESULTS—There were no significant (P > 0.10) interactions of treatment by age (<65 or 65 years), type of diabetes (type 1 or type 2), duration of diabetes (median split <9.18 or 9.18 years), duration of diabetic neuropathy (<2, 2 to <6, or 6 years), severity of diabetic neuropathy (baseline Michigan Neuropathy Screening Instrument score <5 or 5), baseline A1C level (median split <7.6 or 7.6%), or baseline insulin use (yes/no). Significant interactions for both pain measures were observed in baseline pain subgroups (Brief Pain Inventory average pain, 6 and <6). Duloxetine was more effective in the subgroup with more pain. No significant association was found between any other subgroups (P > 0.10). Significant interactions (P < 0.1) occurred with treatment-emergent adverse events when stratified by subgroups.

CONCLUSIONS—Pain severity but not variables related to diabetes or neuropathy may predict the effects of duloxetine in diabetic peripheral neuropathic pain. The efficacy of duloxetine is related to the initial pain severity and is generalizable across a broad spectrum of diabetic patients, including those with the highest severity of diabetes or neuropathy.

Abbreviations: DPNP, diabetic peripheral neuropathic pain

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. Ziegler Treatment of Diabetic Neuropathy and Neuropathic Pain: How far have we come? Diabetes Care, February 1, 2008; 31(Supplement_2): S255 - S261. [Abstract] [Full Text] [PDF]

				J. Katz, N. B. Finnerup, and R. H. Dworkin Clinical trial outcome in neuropathic pain: Relationship to study characteristics Neurology, January 22, 2008; 70(4): 263 - 272. [Abstract] [Full Text] [PDF]